• 대한수의사회지
• /
• 제33권11호
• /
• pp.683-691
• /
• 1997

금세기초부터 갖가지 물질이 vaccine에 가해졌으며, 일정한 처방이 vaccine을 더욱 유효하게 만들기 위해서 고안되고 있다. 많은 선택권에도 불구하고 다만 aluminium 염(鹽)만이 사람용 vaccine adjuvant(면역응답강화물질)로 받아들여지고 있으며, 수의(동물)용 vaccine도 크게 aluminium 염의 사용에 의존하고 있다. 현재 많은 새로운 vaccine들이 개발되고 있으나 vaccine당 구성분의 수를 증가시키고 또한 vaccine 과정에서 요구되는 dose 수를 줄이는 vaccine 접종 schedule을 단순화시키고져 하는 욕구가 대두되고 있다. 이제 더욱 유효한 adjuvant들이 이 욕구를 성취시키기 위해서 요구되는 것이다.

• 대한미생물학회지
• /
• 제6권1호
• /
• pp.15-20
• /
• 1971

Brucella melitensis균의 치사량($10^6{\gamma}$)의 Gamma선을 조사해 줌으로써 만든 Vaccine과 가온 또는 화학처치법(ether, formalin, phenol)에 의하여 만든 Vaccine을 생쥐에 접종하여 그 면역성부과능력에 대하여 비교실험 해본 결과, Gamma선 조사에 의하여 만든 Vaccine이 보다 좋은 성적을 가져왔음을 알게 되었다. 생균 Vaccine Brucella-abortus strain 19과 Brucella melitensis의 R-form을 대량 주사 해 주었을때 생쥐에 치명적이었으며, 7종의 adjuvant에 대한 효력비교실험은 Freund's complete adjuvant와 aluminum-potassium sulfate와 pectin을 섞어 만든 adjuvant를 제외하고는 그리 의의있는 차이를 발견하지 못했다.

• Journal of Microbiology and Biotechnology
• /
• 제28권1호
• /
• pp.136-144
• /
• 2018

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. Bacillus Calmette-$Gu\acute{e}rin$ (BCG) vaccine is the only TB vaccine currently available, but it is not sufficiently effective in preventing active pulmonary TB or adult infection. With the purpose of developing an improved vaccine against TB that can overcome the limitations of the current BCG vaccine, we investigated whether adjuvant formulations containing de-O-acylated lipooligosaccharide (dLOS) are capable of enhancing the immunogenicity and protective efficacy of TB subunit vaccines. The results revealed that the dLOS/dimethyl dioctadecyl ammonium bromide (DDA) adjuvant formulation significantly increased both humoral and Th1-type cellular responses to TB subunit vaccine that are composed of three antigens, Ag85A, ESAT-6, and HspX. The adjuvanted TB vaccine also effectively induced the Th1-type response in a BCG-primed mouse model, suggesting a potential as a booster vaccine. Finally, the dLOS/DDA-adjuvanted TB vaccine showed protective efficacy against M. tuberculosis infection in vitro and in vivo. These data indicate that the dLOS/DDA adjuvant enhances the Th1-type immunity and protective efficacy of the TB subunit vaccine, suggesting that it would be a promising adjuvant candidate for the development of a booster vaccine.

• 한국해양생명과학회지
• /
• 제4권1호
• /
• pp.1-13
• /
• 2019

Fucoidan(후코이단)은 주로 갈조류에서 추출되는 fucose를 함유한 함황 다당류의 일종으로, 항균, 항바이러스 및 항종양 효과와 함께 다양한 경로로 면역력을 향상시키는 생리 기능성물질로 알려져 있다. 최근 연구에 따르면, 인체 백신 분야에서는 fucoidan의 백신 adjuvant(항원보조제)로서의 가능성이 제시되었다. 수산업 분야에서는, 보조사료로서의 fucoidan의 기능에 관한 연구는 보고되고 있으나, 수산용 백신 개발을 위한 adjuvant 연구는 전무한 실정이다. 동물세포에서 fucoidan의 adjuvant에 대한 긍정적인 검토와 함께 안전성을 증명한 연구는 많이 있지만, fucoidan을 어류 백신용 adjuvant로 사용하기 위해서는 어류에서도 이를 확인할 필요가 있다. 또한 fucoidan의 분자량에 따라 세포 내 흡수율이 각기 다르다는 점과 병원체의 인위감염에 따른 항체 생성을 포함한 어류의 특이면역 반응 시스템에 대한 연구가 많이 부족하다는 제약이 있다. 따라서 이러한 분야에 대한 적극적인 연구가 뒷받침 된다면 안전하고 효과적인 adjuvant로 사용할 수 있을 것이다. 본 연구에서는 fucoidan이 사람과 동물을 포함하여 어류의 면역자극 즉 체액성 및 세포성 면역에 미치는 영향에 대한 연구를 검토하고, 수산업 분야에서 fucoidan의 사용과 어류 백신용 adjuvant로서의 가능성을 고찰하였다.

• 한국동물위생학회지
• /
• 제43권2호
• /
• pp.89-97
• /
• 2020

This study was carried out to examine a novel inactivated Salmonella Typhimurium (S. Typhimurium) vaccine candidate for protection of mice against salmonellosis by immunization of BALB/c mice using various type adjuvant. The novel type-inactivated vaccine candidate was constructed by adding Chlorhexidine digluconate solution. BALB/c mice were divided into 6 groups of 15 mice apiece. The mice were intramuscularly (IM) primed at 6 weeks of age and were IM boosted 8 weeks of age. Groups A and B mice were injected with sterile phosphate-buffered saline as controls; group C mice were inoculated with 5×10⁸ cells/100 µL of formalin-inactivated S. Typhimurium cells and adjuvant ISA70; groups D~F mice were immunized with 5×10⁸ cells/100 µL of the inactivated vaccine candidate and adjuvant ISA70, adjuvant IMS1313 and adjuvant IMS1313 containing 30 ㎍/mL of GI24, respectively. All mice (except group A mice) were orally challenged with a virulent S. Typhimurium strain at 10 weeks of age. Mice from groups C-F had significantly increased IgG levels compared to control groups (A-B) mice. The levels of splenocyte IFN-γ and IL-4 in mice of all groups were measured by ELISA, resulting in increased immunity in group F mice compared to those of groups A-E mice. These data suggested that systemic and cell-mediated immune responses were highly induced by IM immunization with the vaccine candidate and adjuvant IMS1313 containing GI24. Furthermore, clinical signs such as death were observed in only 20% of group F mice after virulent Salmonella strain challenge, however, groups B and C (100%), and groups D and E (60%) mice died. This data suggested that mice immunized by intramuscular prime and booster with this vaccine candidate and adjuvant IMS1313 containing GI24 effectively protected mice from salmonellosis.

• 생약학회지
• /
• 제43권1호
• /
• pp.32-38
• /
• 2012

To examine the potentiation of Macrolepiota procera extracts (MPE-4) to act as adjuvant enhancing the tumor specific anti-tumor immune response, tumor vaccine prepared by boiling (HK vaccine) admixed with MPE-4 and immunized in mice. Vaccination of mice with HK vaccine in combination with MPE-4 resulted in higher inhibition in tumor metastasis compared with the mice of HK vaccine alone treatment against live syngeneic tumor cell challenge. The splenocytes from mice immunized HK vaccine mixed with MPE-4 was able to elicit a stronger cytotoxic T lymphocyte (CTL) response as compared with HK vaccine alone. In addition, the splenocytes from MPE-4 admixed HK vaccine immunized mice secreted a higher concentration of Th1 type cytokine such as IFN-${\gamma}$, and GM-CSF. Furthermore, the adoptive transfer of splenocytes from mice immunized HK vaccine and MPE-4 led to a more robust anti-tumour response than the HK vaccine alone. Overall, these results indicate that MPE-4 is a good candidate adjuvant of anti-tumor immune response.

• 한국수산과학회지
• /
• 제54권5호
• /
• pp.652-659
• /
• 2021

Microorganism-derived compounds, such as peptidoglycan, lipoteichoic acid, and β-glucan were supplemented in the scuticociliate Miamiensis avidus (M. avidus) vaccine to verify the specify component contribution to the adjuvant effect. Vaccine was formulated with the inactivated M. avidus antigen (YS2, 4.44×10⁵ cells/fish) in combination with either peptidoglycan (10 ㎍ and 100 ㎍/fish), lipoteichoic acid (5 ㎍ and 50 ㎍/fish), or β-glucan (10 ㎍ and 100 ㎍/fish). Olive flounder injected with peptidoglycan supplemented vaccine (10 ㎍ and 100 ㎍/fish) exhibited significant protection, and the relative percent survival (RPS) was 55% and 65% at 4 weeks post vaccination (wpv), respectively, at the corresponding doses. The vaccine groups with added lipoteichoic acid (5 ㎍ and 50 ㎍/fish) exhibited RPS of 40% and 5%, respectively. Additionally, the group with added β-glucan (100 ㎍/fish) exhibited RPS of 35%, but no effect was observed in the group with added 10 ㎍/fish β-glucan. At 8 wpv, olive flounder injected with peptidoglycan and lipoteichoic acid supplemented vaccines exhibited protection with RPS range of 11/11% and 5/21%, respectively, at the respective doses. M. avidus vaccine containing 10 ㎍ and 100 ㎍/fish of β-glucan exhibited the RPS of 32% and 37%, respectively. Conclusively, peptidoglycan contributed in high protection of the M. avidus vaccine, and thus, it can be used as an effective adjuvant in the M. avidus vaccine.

• IMMUNE NETWORK
• /
• 제20권4호
• /
• pp.33.1-33.19
• /
• 2020

We tested how adjuvants effect in a cancer vaccine model using an epitope derived from an autoactivation loop of membrane-type protease serine protease 14 (PRSS14; loop metavaccine) in mouse mammary tumor virus (MMTV)-polyoma middle tumor-antigen (PyMT) system and in 2 other orthotopic mouse systems. Earlier, we reported that loop metavaccine effectively prevented progression and metastasis regardless of adjuvant types and TH types of hosts in tail-vein injection systems. However, the loop metavaccine with Freund's complete adjuvant (CFA) reduced cancer progression and metastasis while that with alum, to our surprise, were adversely affected in 3 tumor bearing mouse models. The amounts of loop peptide specific antibodies inversely correlated with tumor burden and metastasis, meanwhile both T_H1 and T_H2 isotypes were present regardless of host type and adjuvant. Tumor infiltrating myeloid cells such as eosinophil, monocyte, and neutrophil were asymmetrically distributed among 2 adjuvant groups with loop metavaccine. Systemic expression profiling using the lymph nodes of the differentially immunized MMTV-PyMT mouse revealed that adjuvant types, as well as loop metavaccine can change the immune signatures. Specifically, loop metavaccine itself induces T_H2 and T_H17 responses but reduces T_H1 and T_reg responses regardless of adjuvant type, whereas CFA but not alum increased follicular T_H response. Among the myeloid signatures, eosinophil was most distinct between CFA and alum. Survival analysis of breast cancer patients showed that eosinophil chemokines can be useful prognostic factors in PRSS14 positive patients. Based on these observations, we concluded that multiple immune parameters are to be considered when applying a vaccine strategy to cancer patients.

• Biomolecules & Therapeutics
• /
• 제2권2호
• /
• pp.108-113
• /
• 1994

Toxicity study of recombinant hepatitis B vaccine (LBD-008), a newly developed drug for acute and chronic hepatitis, was investigated in mice and guinea pigs. 1. Mice showed no production of antibodies against LBD-008 inoculated with aluminum hydroxide gel (Alum) as an adjuvant, judged by the heterologous anaphylaxis (PCA) test using rats. On the other hand, antibodies against ovalbumin (OVA) inoculated with alum were definitely detected. 2. In the studies with guinea pigs, both the inoculation of LBD-008 only and of LBD-008 with complete Freund's adjuvant (CFA) as an adjuvant did not produce positive reactions in any of homologous active systemic anaphylaxis (ASA). On the other hand, the inoculation of ovalbumin with complete Freund's adjuvant (CFA) produced positive reaction in both of PCA and ASA. 3. These findings suggested that LBD-008 has no antigenic potential in mice or guinea pigs.

• 한국어병학회지
• /
• 제31권1호
• /
• pp.35-39
• /
• 2018

Atypical furnculosis caused by atypical Aeromonas salmonicida, is an emerging problem of farming of rockfish (Sebastes schlegeli) in Korea. In this study, protection against atypical furunculosis was compared in rockfish vaccinated with A. salmonicida formalin killed cell (FKC) and adjuvant containing FKC. The formalin inactivated A. salmonicida vaccine provided a low protection of 20% and 10% relative percent survival (RPS) at 44 and 58 days post vaccination. However, addition of adjuvant (squalene and aluminum hydroxide) into inactivated A. salmonicida vaccine clearly enhanced the level of protection showing 70% and 50% RPS at 44 and 58 days post vaccination.